Embedded World: ReFLEX CES Introduces the 1st Arria 10 SoC System-On-Module, Named “Achilles”
9.3.2017 08:00 | Business Wire
ReFLEX CES, a leading European-based provider of custom embedded and complex systems, will showcase its expertise in the design and manufacturing of complex FPGA boards at the Embedded World tradeshow. Highlights of the stand include Networking & Processing FPGA boards, Instant-DevKits, OpenCL demos and the new Achilles System-On-Module.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170309005020/en/
Achilles Arria 10 SoC module
The Embedded World tradeshow provides the perfect platform for ReFLEX CES to reveal how it is further extending its proven position as a key provider of SoC FPGA-based solutions.
Special highlight – Achilles FPGA SoC
ReFLEX CES is highlighting at this exhibition its new Achilles (Arria 10 SoC) System-On-Module, offering four standardized FMC interfaces to give users a unique, flexible, fast designing high-end solution. The biggest density FPGA-SoC device, an excellent signal integrity, an unequal number of IOs and some other features provides developers the best in class experience.
Achilles is targeting a wide range of markets including Video Broadcast, Intelligent and Machine Vision, High end Industrial, Military, Test & Measurement and Medical.
A CANBus demo will be hold on the booth based on Achilles Arria 10 SoC System-On-Module integrating the CAN IP to support various Industrial applications.
ReFLEX CES will also highlight its two Low Profile PCIe Network Processing FPGA Board. The XpressGXA10-LP1150 FPGA board with an Altera (Intel PSG) Arria 10 GX FPGA, and the XpressVUP-LP9PT with a Virtex UltraScale+ FPGA. They both are designed for HPC, Finance and Networking applications, the XpressGXA10 being specialized in Ultra Low latency applications.
ReFLEX CES will in addition demonstrate its OpenCL BSP Reference Designs
on its Arria 10 GX PCIe board like High Performance Computing (HPC) and
also 10G MAC (for Low Latency applications).
This offers users like Software engineers who are not familiar to FPGAs and their design flow, a quick and easy way of implementing complex parallel algorithms on a 100% FPGA accelerator target.
Leveraging the benefits of leading edge process technologies, proven transceiver and memory interface technology, the FPGA technology provides an unprecedented level of system bandwidth with superior signal integrity. Combined with the ReFLEX CES’ experience, the produced boards guarantees customers a continuous access to the best on the market.
To schedule a meeting with ReFLEX CES, please email firstname.lastname@example.org.
About Reflex CES
Recognized for its expertise in high-speed applications, analog and
hardened systems, ReFLEX CES has become a leading partner with major
ReFLEX CES simplifies the adoption of FPGA technology with its leading edge FPGA-based custom embedded and complex systems. ReFLEX CES FPGA network platforms enables a better flexibility and ease of programming, offering a faster and most powerful board, and reducing the customers’ technology risks.
For more information, visit http://reflexces.com
Eric PENAIN, +33(0)169870255
Sales & Marketing Director
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
IFF to Present at the Barclays Global Consumer Staples Conference21.8.2017 20:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, today announced that Andreas Fibig, Chairman and Chief Executive Officer will present at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7, 2017 at 11:15 a.m. EDT. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for explorati
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform21.8.2017 20:11 | Pressemelding
Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including: Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets Proprietary allogeneic (“readily accessible”) immunotherapy platform 200+ issued and pending patents in cell therapy
European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25 | Pressemelding
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the
IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00 | Pressemelding
IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman
PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03 | Pressemelding
PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate
Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00 | Pressemelding
Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom